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Although methotrexate (MTX) is one of the most 
clinically effective therapies employed to treat psori-
asis, the mechanism by which low-dose MTX acts to 
modulate the hyperplasia of psoriasis, leading to the 
restoration of clinically normal skin, is only partially 
understood. MTX has been considered a cytotoxic 
agent that mediates its effect primarily on proliferat-
ing or cycling epidermal cells. Recently, proliferat-
ing lymphoid cells have been identified in psoriatic 
lesions, raising the possibility that proliferating lym-
phoid cells could be another target cell that is killed 
by MTX. In this study, we examined the growth-
inhibitory and cyt otoxic effects of MTX on prolifer-
ating lymphoid cells [THP-1 (macrophage), and 
MOLT-4 (T cell)], epithelial cells (HeLa, and HaCat), 
and nonnal human keratinocytes (NHK) in vitro. The 
ethotrexate (MTX) is one of the most effective 
systemic therapies of psoriasis [1,2]. Previous 
studies have suggested that the hyperprolifera-
tive keratinocyte is the cellular target of MTX 
therapy [3- 5]. Clinical experience, however, 
demonstrates that M TX, when administered once weekly, is effec-
tive in clearing psoriasis without clinical evidence of skin necrosis 
[1,2] . With the advent of cyclosporine therapy of psoriasis, recent 
investigations suggest that activated proliferating lymphocytes are 
important in the path ogenesis of psoriasis [6-9]. Similarly, MTX 
may be mediating its therapeutic effect in psoriasis, to some extent, 
through its action on activated proliferating lymphoid cells [9,10]. 
In this study we evaluate the hypothesis that proliferating 
activated lymphoid cells may be an important therapeutic target of 
systemic "low-dose" MTX therapy in psoriasis. In the experiments 
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proliferating cells were exposed to MTX for 24 h, and 
placed in fresh media to mimic the transient MTX 
blood levels that result from once-weekly therapy. 
THP-1 and MOLT-4 were found to be 10-100 times 
more sensitive to the cytotoxic effects of MTX than 
were HeLa and HaCat, and more than 1000 times 
more sensitive than primary human keratinocytes. At 
MTX concentrations that would be expected to occur 
in vivo during once-weekly therapy, a large percent-
age (>95%) of proliferating lymphoid targets would 
be killed, and only a small percentage «10%) ofprolif-
erating epidermal cells would be affected. This in vitro 
data suggests that in psoriasis proliferating lymphoid 
cells are more likely than epithelial cells t o be a major 
cellular target of MTX in vivo. Key words: lymphocytel 
keratinocyte. ] Invest Dermatol 104:183-188, 1995 
being reported, we examine the relative sensitivity of proliferating 
lymphoid and proliferating epithelial cells to MTX administered 
over 24 h (which mimics the blood levels that occur in vivo after a 
single MTX dose) [11- 13]. These experiments evaluate whether 
lymphoid cells and/or epithelial cells are killed or grow th inhibited 
at MTX concentrations achieved during weekly MTX therapy that 
may result in long- term cumulative improvement in psoriasis . 
MA TERlALS AND METHODS 
Cell C ultu re and T ar get-Cell Selection The human epidermal kera-
tinocyte cell line, HaCaT, and HeLa (D98) were obtained from E. 
Stanbridge (Irvine, CA) and maintained in Dulbecco's modified Eagle's 
medium (MEM) supplemented with 10% bovine calf serum (BCS). MOLT 
4 (T cell) and THP-1 (monocyte) were obtained from G.A. Granger (Irvine, 
CA) and maintained in RPMI 1640 supplemented with 10% BCS. Primary 
cultures of normal human keratinocytes (NHK) were passaged into modi-
fied complete MCDB 153 medium containing the standard growth factors, 
hormones, supplements [epidermal growth factor (EGF), insulin, and BPE] 
and nutrients, and NHK were cultivated as previously described [14]. These 
cell lines were chosen to mimic the rapid proliferation seen in activated 
proliferating lymphoid cells and hyperproliferative epidermis found in 
psoriasis. 
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Exposure of Lymphoid Cells to MTX 
Cell Viability and Viable Cell Counts After Exposure to MTX: In each 
experiment, six 1O-ml cultures of MOLT 4 or THP-1 were established in 
RPMI 1640 (10% BCS) at a density of 0.3 X 106/ml in T25 tissue-culture 
B.asks and were incubated at 37°C. MTX was added to five cultures such 
that the final concentrations were 10- 5 M to 10-9 M and the sixth culture 
was employed as an untreated control culture. In one set of experiments 
MTX was left in the media during the entire incubation. In a second set of 
experiments all six cultures were incubated at 37°C for 24 h, after which the 
cells in each B.ask were spun down, washed, and resuspended in 5 ml of fresh 
RPMI 1640 (10%) tissue-culture media. These cultures were incubated at 
37°C for up to 6 dafter MTX exposure. Viable cell number was assessed 
each day employing a hemocytometer and trypan blue dye exclusion. 
Cloning Efficiency After MTX Exposure: The number ofTHP-1 cells surviv-
ing exposure to MTX was assessed by measuring the ability of THP-1 cells 
to form colonies in soft agar after a 24-h exposure to MTX. THP-1 cells 
were set up in 24-well plates at 0.3 X 106 /ml in RPMI 1640 10% fetal 
bovine serum and exposed to MTX at concentrations ranging from 10 - 5 M 
to 10- 10 M for 24 h. After the exposure the cells were washed, plated in 
0.5% soft agar in petri dishes, and grown at 37°C in a humidified CO2 
incubator for 12 d. The number of colonies that were measured at the 
beginning of the MTX exposure was defined as 100%, and the numbers of 
colonies after exposure to different concentrations of MTX were expressed 
as the percent of starting cell number. 
Exposure of HaCaT and HeLa Epithelial Cells to MTX 
Cell Viability and Viable Cell Counts After MTX Exposure: Tissue-culture 
plates were seeded with HeLa or HaCaT cells and incubated overnight. 
MTX was added to each well in concentrations ranging from 10-3 M to 
10 - 8 M, and the culture was incubated for 24 h at 37°C. Mter removing the 
MTX-containing medium, the cells were washed two times, and then fresh 
medipm added to the well. Individual cultures were incubated an additional 
1 to 6 d before assessing viable cell number per well in 6- or 24-well 
tissue-culture plates. Viable cell number per well was assessed by trypsiniz-
ing the cells and counting viable cell number employing trypan blue and a 
hemocytometer. 
Cloning Efficiency After MTX Exposure: The ability of He La and HaCaT to 
form colonies after exposure to MTX was assessed. HeLa and HaCaT were 
plated in 6-well plates at a density of200-1000 cells per plate and incubated 
overnight to allow the cells to attach and recover from the trypsin 
treatment. MTX was added to each plate at concentrations ranging from 
10- 5 M to 10- 8 M for 24 h. The MTX-containing media was removed, the 
plates washed, fresh media added, and the plates incubated for 6 -12 d 
before counting the number of colonies. 
Exposure of NHK to MTX 
Cell Viability and Viable Cell Counts After MTX Exposure: NHK cultures 
growing in MCDB 153 medium containing 0.2 J-LM thymidine (low-
thymidine medium) were exposed to MTX at the designated MTX 
concentration for 24 h. Cultures were thoroughly washed and re-fed with 
complete, low-thymidine culture medium every other day. Cell density was 
determined by trypsinization and direct cell enumeration of duplicate 
cultures as previously reported [14] . Cell viability was assessed by pro-
pidium iodide exclusion using a previously described method [15]. 
Cloning Efficiency After MTX Exposure: Following the 24-h MTX exposure, 
and extensive washing to remove the MTX, the colony-forming efficiency 
of MTX-treated cultures was examined in a clonal growth assay. Five 
hundred cells were seeded into 60-mrn dishes containing low-thymidine 
medium, EGF, insulin, and supplements. Ten days later, the dishes were 
fixed and stained, and the colonies were enumerated using a macroscopic 
video imaging camera and mAS image-analysis system (Kontron Elek-
tronik, Munich, Germany) as previously described [14] . 
RESULTS 
An In Vitro Model of uLow-Dose" MTX Therapy of Psori-
asis To design an in vitro model that mimics low-dose MTX 
therapy in vivo, the phannacokinetic data in the literature was 
examined to estimate the duration that MTX is present in the blood 
in levels capable of inhibiting the growth of or killing sensitive 
proliferating target cells. To simplify this analysis, we chose to 
evaluate the phannacokinetics of a single dose of MTX adminis-
tered at weekly intervals. This clinical regimen is an effective 
therapy employed to treat psoriasis when administered at doses of 
12.5-25 mg/week [1,2]. In vitro studies examining proliferating 
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target cells have demonstrated that MTX has negligible biochem-
ical, cytotoxic, or growth-inhibitory effects on proliferating cells il 
vivo or in vitro below 0.01 JLg/ml (2.2 X 10- 8 M); most cytotoxi( 
effects observed in vitro occur above 0.1 JLg/ml (2.2 X 10- 7 M ' 
[3,16-18]. Thus, the duration for which MTX blood levels an 
above 0.01 JLg/ml provides a measure of the total duration fo. 
which MTX is capable of mediating growth-inhibitory effects il 
vivo, and the duration above 0.1 J-tg/ml provides an estimate of th, 
duration for which cytotoxic levels of MTX are present in vivo. 
The MTX blood levels that occur after a single dose of MTX it 
patients with psoriasis and rheumatoid arthritis have been reporte( 
by a number of investigators [11-13]. After a single 25-mg oral dose 
of MTX the blood levels remained above 0.1 J-tg/ml (2.2 X 10- ~ 
M) for 8 h, and above 0.01 JLg/ml (2.2 X 10- 8 M) for 26 h [12]. 
Thus, MTX blood levels exceed minimum cytotoxic or growth-
inhibitory levels for, at most, 24 h after a single oral 25 mg MTX 
dose. This compares well with in vivo studies, demonstrating that 
decreased epidermal proliferation, as measured by decreased 3H_ 
deoxyuridine (UdR) incorporation in psoriatic lesions, can be 
demonstrated for only 18-24 h after a single 25-50 mg dose of 
MTX [3]. 
When MTX is administered weekly to treat psoriatic patients, 
MTX is present for only the first 24 h, and not for the remaining 6 
d. Thus, to a first approximation, MTX therapy can be modeled in 
vitro by exposing cellular targets to varying concentrations of MTX 
for 24 h, washing out the MTX, and then observing the cells' 
viability and proliferative capacity while being maintained in fresh 
tissue culture medium. In the following experiments, proliferating 
lymphoid and epithelial cell lines were exposed to varying concen-
trations of MTX for 24 h and viability and viable cell number were 
assessed before, during, and for 3-12 dafter MTX exposure. 
Correlation of In Vitro MTX Dose and In Vivo MTX Dose 
To determine the relevant in vitro MTX concentrations for these 
studies, the area under the concentration versus time curve (AUe) 
in vivo of clinically effective MTX doses (2.5- 25 mg) was calcu-
lated. The AUe in vivo can be used to determine a comparable 
MTX concentration in vitro to be administered over 24 h to 
generate the same AUe. The effect of this MTX concentration in 
vitro on lymphoid and epithelial cells will presumably reflect the 
growth-inhibitory and cytotoxic effects of MTX in vivo. 
The MTX blood levels that occur during low-dose MTX 
therapy, and the corresponding AUe, have to be estimated because 
no studies to date have reported the blood levels of MTX given in 
increasing doses (2.5-25 mg) to individual patients. The observed 
blood levels of MTX administered orally to psoriatic patients follow 
first-order kinetics after peaking at 1-2 h [11-13]. Thus, if the peak 
concentration achieved at any oral dose can be measured and the 
kinetic decay parameters determined, the MTX blood level versus 
time curve for patients can be calculated. Sinnet et al provided the 
best kinetic half-life data for patients receiving 7.5 mg MTX orally, 
and demonstrated a t1l2 = 4.45 h (range 3.56-5.34 h) [13]. Halprin 
et al provided an analysis of the peak MTX concentration in patients 
as a function of administered MTX dose and found that [peak MTX 
(J-tg/ml)] = [dose (mg/kg)] X [2.76] + 0.21 [11]. Thus, MTX 
blood levels as a function of time [c(t)] can be calculated: c(t) = 
[peak MTX] exp(-kt); (k = ln2/MTX blood half life), after 
reaching peak concentration at 2 h. 
MTX blood levels have been estimated using the pharmacoki-
netic information presented above for a 70-kg patient taking a 
single oral MTX dose in the range 2.5-25 mg MTX. In this model, 
the MTX concentration increases linearly and reaches a peak blood 
level at 2 h, and then decay;; exponentially with a half life of 4.45 
h. The correlation of in vivo therapeutic MTX blood levels to 
concentrations for the in vitro model of psoriasis therapy are given 
in Table I. Based on this analysis, the relevant range of MTX 
concentrations in our in vitro model system that mimics the 
clinically employed 2.5 to 25 mg MTX oral doses is a 24-h 
exposure of 1.5-6.42 X 10-7 M MTX. 
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Table I. Correlation of In Vivo MTX Blood Levels 
\ chieved During Once Weekly MTX Psoriasis Therapy to 
the MTX Concentration Employed in the In Vitro Model 
of Psoriasis Therapy 
Oral MTX 
Dose In Vivoa 
(mg) 
2.5 
5.0 
7.5 
10.0 
15.0 
25.0 
MTX Blood Levels: 
AUC In Vivob 
(nM-h) 
3,657 
4,914 
5,770 
7,409 
9.942 
15,388 
Equivalent MTX Concentration 
in the In Vitro Model SystemC 
(X 10- 7 M) 
1.5 
2.1 
2.4 
3.1 
4.1 
6.4 
a Calculated blood levels generated from an oral dose are based upon a 70-kg body 
weight. The mg/kg dose ranges from 0.036 to 0.357 mg/kg. 
b AUC for the calculated in vivo MTX blood levels out to 24 h were calculated using 
published pharmacologic information because no actual experimental data is available 
to make the comparisons. Assumptions in this calculation are that MTX blood levels 
peak at 2 h [11- 13], that peak blood levels (lLg/ml) = [dose(mg/kg) X 2.75] + 0.21 
[11], from 0 to 2 h the blood MTX levels increase linearly to the peak level, and the 
peak MTX blood levels decay exponentially with a halflife of 4.45 h [13]. 
( This MTX concentration represents the calculated concentration ofMTX given for 
24 h that generates the same AUC that the il1 vilJO exposure produced. AUC MTX 
blood levels il1 vivo = AUC in vitro in the psoriasis model = MTX concentration X 24 h. 
Effect of MTX on the Growth and Viability of Lymphoid 
Cells The first experiments examine the sensitivity of proliferat-
ing THP-l (monocyte) cells to MTX-mediated growth inhibition 
and cytotoxicity. The effect of a 24-h exposure of various concen-
trations of MTX on growth and viability of THP-l is presented in 
Fig 1. A 24-h exposure to 10- 7 M or higher MTX concentration 
leads to a sustained net decrease in viable cell number up to 168 h 
(1 week), whereas exposure to 5 X 10 - 8 M MTX for 24 h does not 
produce a net decrease in cell number below the starting cell 
number. 
MOLT- 4 cells (T cells) were treated with various concentrations 
of MTX for 24 h, as already described, and viable cell number was 
assessed. MTX concentrations of 5 X 10 - 8 M or greater produced 
a decrease in viable cell number below starting cell number (Fig 2). 
The period below the starting cell number was transient for 5 X 
10- 8 M MTX, and cell number exceeded the starting cell number 
by 80 h of culture. At MTX concentrations 10- 7 M or greater the 
decrease in cell number below the starting cell number persists to 
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Figure 1. THP-l growth curve. Cells exposed to MTX for 24 h (0-24 
h), washed, and then placed in fresh medium (24-160 h). Viable cell 
number per milliliter measured at indicated times, and data represents the 
mean ± SD of two experiments . MTX concentrations during the first 24 h: 
media (e ), 1 X 10- 8 M (0), 5 X 10- 8 M (A), 1 X 10- 7 M (6), 1 X 10- 6 
M (_ ). 1 X 10- 5 M (0). 
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Figure 2. MOLT-4 growth curve. Cells exposed to MTX for 24 h (0-24 
h). washed. and then placed in fresh medium (24-160 h). Viable cell 
number per ml measured at indicated times, and data represents the mean ± 
SD of two experiments. MTX concentrations during the first 24 h: media 
(e ), 1 X 10- 8 M (0 ). 5 X 10- 8 M (A ). 1 X 10- 7 M (,0,), 1 X 10- 6 M (_ ). 
1 X 10- 5 M (D). 
142 h. Thus, weekly administered MTX will have a cumulative 
effect (i.e., progressive decrease in proliferating lymphocyte num-
ber with weekly MTX therapy) only at MTX concentrations of 
10- 7 M or greater (which are easily achieved in vivo). 
Factors other than cell death contribute to the final number of 
viable cells that would be expected just before the weekly MTX 
dose. The growth of the MOLT or THP cells after the initial 24 h 
would replace some of the cells killed by MTX exposure. This 
would increase viable cell number and decrease the magnitude of 
the final effect of MTX on these lymphoid cells assessed at the week 
interval. With MOLT-4 cultures exposed to 5 X 10- 8 M MTX, 
regrowth of cells after 80 h can be demonstrated. With continuous 
MTX exposure (data not shown) MTX was much more effective, 
and, as exp.ected, no regrowth was seen with either MOLT -4 or 
THP-l during the 6-d culture. 
Effect ofMTX on HeLa (Epithelial) And HaCaT (Epidermal) 
Cells The cytotoxic and anti-proliferative effects of a 24-h expo-
sure of HeLa cells to MTX were examined. A 24-h exposure to 1 
X 10 - 7 M or 2 X 10 - 7 M MTX decreases viable HeLa cell number 
only a small amount (Fig 3). MTX concentrations of 1 X 10- 6 M 
and greater are required to substantially decrease viable cell number 
particularly aftet 5 to 6 d. As with THP-1 and MOLT-4, the 
decrease in viability is apparent after about 40 h (16 h after the 
MTX is removed from the culture). Comparing the data in Fig 3 
with the data in Figs 1 and 2 demonstrate that HeLa cells require 
approximately 10 times the dose of MTX to obtain growth curves 
similar to those obtained with THP-1 and MOLT 4 . 
The cytotoxic and growth-inhibitory effect of a 24-h MTX 
exposure on HaCaT epidermal cells was next examined. The data 
in Fig 4 demonstrate that a concentration greater than or equal to 
1 X 10 - 6 M MTX results in a sustained decrease in viable cell 
number. A 24-h treatment with 10 - 7 M MTX leads to only a 
transient decrease in viable cell number. Treatment of these cells 
with weekly MTX in the clinically relevant range (1-5 X 10- 7 M) 
in this model would not be expected to decrease cell number at the 
end of one week. Because a net decrease in proliferating cells is not 
produced at clinically relevant MTX concentrations, clinical im-
provement (i.e., net decrease in proliferating lesional keratinocytes) 
would not be expected to occur with weekly MTX therapy. 
Effect of MTX on Normal Human Keratinocytes (NHK) 
The cytotoxic and growth-inhibitory effects of a 24-h MTX 
exposure on normal human keratinocytes was next examined. To 
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Figure 3. HeLa growth curve. Cells exposed to MTX for 24 h (0-24 h), 
washed, and then placed in fresh medium (24-120 h). Viable cell number 
per well measured at indicated times, and data represents the mean ± SD of 
two experiments. MTX concentrations during the first 24 h : media (e ), 1 
x 10- 7 M (L.), 2 X 10- 7 M ( X ), 1 X 10- 6 M (_ ), 1 X 10- 5 M (0), 1 X 
10- 4 M (0 ). 
mimic the in vivo conditions, MCDB 153 culture medium contain-
ing thymidine at a concentration of 0.2 /LM was prepared. This 
thymidine concentration approximates the observed in vivo serum 
concentrations of thymidine (0.33 ± 0.16 /LM) in normal individ-
uals [19], and also approximates the in vitro concentrations of 
thymidine in tissue-culture media containing 10% bovine serum 
that was employed to grow the other cell lines [20]. The data in Fig 
5 demonstrates that only growth inhibition was obtained with 
MTX exposures as high as 10- 5 M for 24 h. No evidence of a 
decrease in cell number, cell death, or differentiation at all MTX 
concentrations (including 10- 5 M MTX) was see n. At an MTX 
concentration of 10 - 7 M only transient growth inhibition was 
noted. Other studies with thymidine free media demonstrated only 
growth inhibition when evaluated 48 h after MTX exposure (data 
not shown). This growth inhibition was overcome with medium 
containing normal (high) levels of thymidine. There was no 
evidence that the growth inhibition produced by MTX exposure 
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Figure 4. HaCaT growth curve. Cells exposed to MTX for 24 h (0 - 24 
h), washed, and then placed in fresh medium (24-160 h). Viable cell 
number per well measured at indicated times, and data represents the mean 
± SD of two experiments. MTX concentrations during the first 24 h: media 
(e), 1 X 10- 9 M (A.), 1 X 10- 8 M (0), 1 X 10- 7 M (L.), 1 X 10- 6 M (_) , 
1 X 10- 5 M (0). 
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Figure 5. NHK growth curve. Cells exposed to MTX for 24 h (0-24 h) , 
washed , and then placed in fresh medium (day 1 to day 13). Viable cell 
number per cm2 measured at indicated times, and data represents the mean 
± SD of duplicate measurements. MTX concentrations during the first 24 
h: media (e ), 5 X 10- 8 M (.), 1 X 10- 7 M (L.), 1 X 10- 6 M (_ ), 1 X 10- 5 
M (0). 
had induced the cells to irreversibly growth arrest and terminally 
differentiate. 
Cloning Efficiency ofTHP-1, HeLa, HaCaT, and NHK Cells 
After a 24-h MTX Exposure The growth curves of MTX-
treated cells, presented thus far, assess the combined measures of 
both cell death and cell growth as a function of time. Therefore, 
specific studies were performed to examine the cytotoxic effects of 
MTX using a cloning efficiency assay. In the cloning assays the 
confounding effects of delayed cellular death and slowed growth 
rate of the cell line under test is eliminated. The ability of THP-l, 
HeLa, HaCaT, and NHK to grow into colonies after a 24-h 
exposure to 10 - 5 M to 10 - 8 M MTX is shown in Fig 6. In these 
studies, THP-l cells are the most sensitive cellular target to 
MTX-mediated cytotoxicity, whereas NHK is the most resistant. 
THP-l plating efficiency is reduced by more than 95% when 
exposed to 10 - 7 M MTX for as little as 8 h (data not shown). No 
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Figure 6. Cytotoxic MTX activity. Proliferating cells exposed to MTX 
for 24 h at the indicated concentrations, washed, and allowed to grow into 
individual colonies. Data represents the mean ± SD of duplicate tests. 
Control cells washed with media only represent 100% cloning efficiency. 
THP-1 (e ), HeLa (. ), HaCaT (_ ), primary human keratinocytes (0). 
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,ignificant decrease in plating efficiency of NHK was seen after a 
24-h exposure to 10- 5 M MTX. 
Comparing the relative sensitivity of the various cells at the 
concentration at which 50% plating efficiency occurs using THP-1 
as a baseline of 1, HeLa are 12 times, HaCaT are 97 times, and 
NHK are more than 1563 times more resistant to MTX than are 
THP. At the expected concentrations achieved during low-dose 
MTX therapy (1-5 X 10- 7 M), 95-99% of THP cells would be 
expected to die, whereas only a small percentage «10%) of 
pidermal keratinocytes would be killed. 
DISCUSSION 
The mechanism(s) by which low-dose MTX administered weekly 
acts to modulate the epidermal hyperplasia seen in psoriasis leading 
to the restoration of clinically normal skin is still only partially 
understood. MTX and other antimetabolites used to treat psoriasis 
have been considered cytotoxic agents that mediate their effects 
primarily on proliferating or cycling epidermal cells [3-5]. In 
psoriasis, both local (intralesional) and systemic MTX inhibit de 
novo epidermal DNA synthesis [3H-deoxyuridine (UdR) incorpo-
ration], decrease mitotic activity and produce histologically "dam-
aged" epidermal cells [3-5]. On the basis of these observations it 
has been assumed that local cytotoxic effects on proliferating 
keratinocytes are responsible for the therapeutic activity of MTX in 
psoriasis. However, MTX administered weekly to treat psoriasis 
does not cause clinically evident necrosis of psoriasis plaques [2,3], 
and rarely affects other rapidly proliferating epithelial cells or other 
tissues (e.g., hair, bone marrow, or gastrointestinal epithelium). 
Biopsies of psoriatic skin after MTX therapy reveal that only a very 
small percentage of keratinocytes [less than 100 keratinocytes per 
4-mm section of psoriatic epidermis « 1 %) are" damaged"] [3,5]. 
This suggests that pathways other than direct cytotoxic effects on 
keratinocytes may be involved in MTX's action in psoriasis. 
Another less well-known observation is that locally administered 
(intralesional or topical) MTX, which provides adequate tissue 
delivery comparable to that obtained with low dose MTX therapy 
[21-24], does not produce significant clinical improvement of 
psoriatic skin lesions [25-28]. This finding suggests that direct 
effects of MTX on psoriatic epidermal cells are not the primary 
mechanism of action by which MTX exerts its activity in psoriasis. 
Because systemically administered MTX is clinically effective, and 
locally administered MTX is not effective, we postulate that MTX 
may mediate some of its therapeutic effects at sites other than the 
skin. Because many studies suggest a role for the immune system in 
psoriasis, we hypothesize that activated lymphoid cells (i.e., prolif-
erating lymphoid cells) in various tissue compartments (e.g., lymph 
nodes, spleen, blood, skin) may be a major target of systemically 
administered MTX in psoriasis. 
The available data suggest that MTX mediates its effects on 
cellular proliferation of keratinocytes while the drug is present 
during the first 24 h following a therapeutic administration of a 
single dose of MTX [3]. Inhibition of DNA synthesis in keratino-
cytes and "damaged" keratinocytes are only seen for 18-24 h after 
administering MTX. Serum MTX levels, after a single MTX dose, 
are not biochemically significant by 18-24 h [11,12]. This data also 
demonstrates that hyperproliferative growth of epidermal cells 
indistinguishable from pretreatment occurs il1 vivo by 18 -24 h after 
a single MTX dose [3]. This last observation suggests that there is 
no cumulative growth-inhibitory effect on keratinocytes after 
weekly doses of MTX in vil/o. 
In the model system developed in this study, proliferating 
lymphoid and epithelial cells were exposed to MTX for 24 h in vitro 
to mimic the transient MTX blood levels that occur during weekly 
MTX therapy in vivo. The cytotoxic and growth-inhibitory effects 
were examined in "itro over the first 24 h of MTX treatment and the 
subsequent 4 - 6 d, when MTX was no longer present in the 
cultures. These experiments demonstrate that lymphoid target cells 
(THP- 1, MOLT-4) are very sensitive to MTX-induced cytotoxicity 
when compared to epithelial cells. At MTX concentrations easily 
reached in patients (1-5 X 10- 7 M MTX), the lymphoid cell lines 
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are effectively killed (>95%) by a 24-h MTX exposure il'l. vitro. It 
takes a 10-100-times higher MTX concentration to obtain approx-
imately equivalent killing with HeLa and HaCaT compared with 
lymphoid cells. Furthermore, normal human keratinocytes were 
not killed, even at concentrations of10- 5 M MTX, and were more 
than 1000 times more resistant to the cytotoxic effects of MTX than 
were THP-1 cells. These data strongly suggest that there is a 
differential sensitivity oflymphoid cells and keratinocytes to MTX, 
and that proliferating activated lymphoid cells in vivo may be a 
major cellular target of MTX therapy in psoriatics. 
We hypothesize that for MTX to have a sustained beneficial 
effect on psoriasis via a cytotoxic and/or growth-inhibitory mech-
anism, the number of proliferating cells at the end of a week (i.e., 
just prior to the next MTX dose) must be less than the number with 
which one started. In the model system presented, a 24-h exposure 
to MTX results in a significant amount of lymphoid cell death but 
only a minimal amount of psoriatic keratinocyte death. The small 
number oflymphoid cells surviving the MTX exposure continue to 
proliferate. At clinically relevant MTX concentrations in this model 
the proliferating lymphoid cells final number does not exceed the 
starting cell number when the next dose of MTX would be 
administered. Thus, each subsequent dose of MTX should result in 
a progressive loss of proliferating lymphoid cells, and this may be 
ultimately expressed as improvement in the psoriatic plaque. Epi-
dermal cells, in contrast, easily replace all the cells killed by MTX 
during the 6-d interval before the next MTX dose. Thus, no net 
decrease in epidermal cells would occur with each weekly dose of 
MTX. 
Although we have been examining the mechanism of action of 
MTX in psoriasis in the current experiments, the in vitro studies 
examining the effect of MTX on proliferating lymphoid cells are 
relevant to the mechanism of MTX in other diseases. MTX is 
effective treatment for several immunologically-mediated autoim-
mune diseases that include psoriasis [2,29,30], psoriatic arthritis 
[31], rheumatoid arthritis (RA) [32], primary biliary cirrhosis [33], 
and adjuvant arthritis [34]. The mechanism by which MTX mod-
ulates the activity of these diseases is unknown. MTX could be 
working 1) locally in the target organ (skin in psoriasis, joints in RA 
and psoriatic arthritis, and liver in primary biliary cirrhosis), or 2) at 
sites distant to the target organ (e.g., lymph nodes, spleen, etc.), or 
3) at both sites. Because MTX has an effect in all these autoimmune 
diseases , this suggests that the primary site at which MTX operates 
is not at the target organ alone. MTX could be working at both the 
target end organ and at sites other than the end organ, or 
alternatively, primarily at non-target end organ sites (e.g., lymph 
nodes, spleen, etc.). Clinical observations in RA have demonstrated 
that MTX injections into affected joints do not improve the joint 
disease [35,36]. This evidence again suggests that MTX may 
mediate its effects at sites other than the target organ that is affected 
by the immune system. 
By combining the in vitro experiments presented in this study 
with the clinical responses observed in psoriasis, RA, and primary 
biliary cirrhosis to MTX, a plausible mechanism of MTX action 
common to all these diseases can be discerned. MTX is not a cure 
in each of these diseases. It controls the active disease while being 
administered, and the disease returns when it is discontinued. Thus, 
it appears that MTX does not permanently alter the fundamental 
pathologic processes generating the autoreactive cells. Because 
MTX is a cytotoxic agent that specifically affects proliferating cells, 
it is reasonable to hypothesize that the target cell(s) are proliferat-
ing. In RA, the number of activated proliferating lymphocytes have 
been demonstrated to be elevated in both the blood and synovium 
[37-40], and to decrease after low-dose MTX therapy [37-40]. 
We hypothesize that MTX may be killing or altering the number of 
activated proliferating effector lymphoid cells involved in mediating 
these autoimmune diseases. The relative contribution of MTX's 
therapeutic effect on circulating activated proliferating lymphoid 
cells and those proliferating cells in the target end organ tissues 
remains to be determined. 
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